HEMOSTEMIX ANNOUNCES DR. MARY ARGENT-KATWALA AS ITS CLINICAL TRIAL MANAGERJune 3, 2020
Calgary, Alberta, June 3, 2020 — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) is pleased to announce the appointment of Dr. Mary Argent-Katwala to the position of Manager, Clinical Trials.
Dr. Argent-Katwala earned her PhD in molecular biology from the Institute of Cancer Research, University of London, UK and her MA (Hons.), Biological Sciences at Newnham College, University of Cambridge, UK.
Previously, Dr. Argent-Katwala was Director, Diagnosis & Clinical Care at the Canadian Partnership Against Cancer, Toronto, ON where she created a portfolio of high-impact investments to address key issues in the diagnosis and treatment of cancer.
Prior to joining the Partnership, Dr. Argent-Katwala held progressive positions with the Decision Resources Group in both Toronto. ON and London, UK, with her most recent assignment being Vice President, Therapy, Reports & Consulting. Dr. Argent-Katwala directed teams analyzing market dynamics, patterns of care and emerging therapies across all therapeutic areas in the G7 and BRIC regions for clients in the pharma, biotech and medical device industries.
“Dr. Argent-Katwala is a great addition to our team,” said Thomas Smeenk, President & CEO. “She has a complete understanding of the science of ACP-01, the track record of generating meaningful analyses of each of our markets to help us focus trials in our key revenue streams, and combines that with the relationship-based experience from which to inspire confidence in our partnerships and our clinical trial programs,” Smeenk said.
“I’m delighted to join Hemostemix at this exciting time for the company and I look forward to advancing the development of ACP-01 and bringing hope to patients and their families,” said Dr. Argent-Katwala.
Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.
On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01Trial With 4.5 Year Follow-up” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.
The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit www.hemostemix.com.
Contact: Thomas Smeenk, President, CEO & Co-Founder
Suite 1150, 707 – 7th Avenue S.W., Calgary, Alberta T2P 3H6, 905-580-4170
Neither the TSX Venture Exchange nor
its Regulation Service Provider (as that term is defined under the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy
of this release.
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the hiring of personnel to complete a series of strategic initiatives related to clinical trials. This forward-looking information reflects Hemostemix’s current beliefs and is based on information currently available to Hemostemix which the Company believes are reasonable. These assumptions include, but are not limited to personnel who will complete strategic initiatives related to the Company’s technology, ACP-01. Results may vary due to the COVID-19 pandemic or other reasons which may effect Hemostemix’s operations including any research, trials or studies that may be impacted. Forward looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability to complete its current CLI clinical trial, complete a satisfactory futility analysis and the results of such and future clinical trials; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in the Company’s markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; the impact that the COVID-19 pandemic may have on Hemostemix may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix’s ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix’s disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
View All News & Media